| dc.description.abstract | The aim of the present study was to evaluate the activity of the NAWAlution WoundCare® solution on various bacteria and to determine its suitability for use in critical care units. The effect of the antiseptic solution, NAWAlution® WoundCare(NAWA Heilmittel GmbH, Germany) was evaluated with and without the addition of albumin, using the broth microdilution method. A total of eight gram negative, four gram positive type bacteria that may be isolated in an intensive care unit and spore-forming bacteria Bacillus spp., as well as C.albicans were studied. E.coli, K.pneumonia, E.faecium, S.aureus and ATCC strains were used in the study. In vitro cytotoxic activity of the NAWAlution WoundCare® antiseptic solution was determined by 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyl tetrazolium bromide test. NAWAlution WoundCare® was found to be effective against K.pneumoniae at a concentration of 1/32; against A.baumanii, P.aeruginosa, Chryseobacterium spp, S.maltophilia and Shewanella at a concentration of 1/64; and against E. coli at a concentration of 1/256. However, no activity was observed against B.cepacia. The substance was effective against MRSA at a concentration of 1/64; against voncomycin-resistant E.faecium, vancomycin-sensitive E.faecium and Bacillus spp. at a concentration of 1/128; against methicillin-sensitive S.aureus and methicillin-resistant coagulase negative staphylococci at a concentration of 1/256; and against C.albicans at a concentration of 1/256. However, NAWAlution WoundCare solution at a concentration of between 1/10 and 1/2560 had no cytotoxic effect on the Vero cells. In conclusion NAWAlution WoundCare® antiseptic solution was found to be effective against many microorganisms that could cause wound infection, and is also appropriate for direct topical application. © 2015, Scientific Publishers of India. All right reserved. | en_US |
